Canadian Blood Services’ Blood Efficiency Accelerator Award Program 2020


Canadian Blood Services

For More Information

For additional information, please visit the program's websites for

  • Program guidelines
  • Application forms
  • Evaluation criteria


The objective of the Canadian Blood Services’ Blood Efficiency Accelerator Program is to improve the efficient and appropriate utilization of blood products, while maintaining the safety of the blood system. To achieve this objective, the Program will support innovative research projects that seek new knowledge or accelerate the application of existing knowledge. In the context of this competition, blood product is defined as a therapeutic product derived from the donation of blood or blood components and includes red blood cell and platelet concentrates, plasma and plasma derivatives (including plasma protein products), and hematopoietic stem cells (including those derived from cord blood). The current competition encourages applications addressing COVID-19 related transfusion challenges while meeting the objective of the Program.

While all applications aimed at improving the efficient and appropriate utilization of Canadian Blood Services’ blood products are encouraged, the current competition will give priority to projects focused on improving procedures and protocols at Canadian hospitals or at Canadian Blood Services that will result in improved utilization of red blood cells, platelets, and plasma products. These improvements may be realized at any point from vein to vein, that is, from the point of blood collection, through the manufacturing, distribution, and blood banking processes, to clinical utilization. Projects with a defined knowledge translation strategy to accelerate the Blood Efficiency Accelerator Program – Guidelines May 2020 Page 2 of 6 Blood Efficiency Accelerator Program Guidelines (attached) uptake of the study findings or of existing knowledge by the knowledge user group will also be prioritized. With respect to COVID-19, applications will be considered in scope if they target improved efficiency of executing and/or improving the measures now necessary to protect hospital or Canadian Blood Services staff or donors or patients from the pandemic, in the delivery of transfusion medicine, and prior to the widespread availability of a vaccine. 


Primary Applicant: The Primary Applicant must be affiliated with a Canadian academic program as a faculty member or with Canadian Blood Services. The Primary Applicant is responsible for submitting the application, delivering the project as approved, and reporting on project progress to Canadian Blood Services.

Team composition: All project teams require at least one Canadian Blood Services employee. All project team members must have a defined role in the project, and their expertise must be clearly required to adequately address project goals. Applicants are encouraged to contact if help is needed to identify a Canadian Blood Services project team member.

Maximum Project Value

maximum $30,000 per grant

Indirect Costs


Project Duration

1 year

Special Notes

Please refer to the Office of Research COVID 19 web-page for directives related to research activities at the University of Guelph.


If College-level review is required, your College will communicate its earlier internal deadlines.

Internal Deadline

Applicant to submit a copy of application along with a complete OR5 form to:

External Deadline

Applicant to submit all documents by email to


PDF icon application guidelines 202083.41 KB
For Questions, please contact

Enquires: Centre for Innovation at or by phone at (613) 739-2564.

Office of Research

Ornella McCarron, Grants Officer
Research Services Office
519-824-4120 x52832

Alert Classifications
Funding Opportunities and Sponsor News

Health and Life Sciences